SN
Syndax Pharmaceuticals, Inc.
SNDX · NASDAQ
$18.07 +1.69% (+$0.30)
1M -9.96%
Market Cap $1.56B
P/E Ratio -
Div. Yield -
ROE 372.94%
Piotroski F-Score Weak
3/9Valuation
12 /100
Expensive P/S 6.20x
P/B 103.41x
P/E N/A
Growth
0 /100
Declining Book val. growth 48.29%
EPS growth N/A
FCF growth N/A
Profitability
20 /100
Weak Gross margin 97.47%
FCF margin 87.64%
Net margin 87.60%
Quality
5 /100
Poor ROIC 32.12%
Asset turnover 0.36x
ROE 372.94%
Debt
23 /100
High Debt/Equity 39.03x
Int. coverage -1.58x
Current ratio 6.77x
Stability
54 /100
Moderate Beta 0.37x
Profitable years 0
EPS volatility 20.28%
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o SNDX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Michael A. Metzger
Employees
298
Headquarters
New York City
Prihajajoči dogodki
02 NOV.
Earnings
Upcoming earnings report